Home / Publication / Population Pharmacokinetics and Exposure-response of Osimertinib in Patients with Non-small Cell Lung Cancer

論文

Population Pharmacokinetics and Exposure-response of Osimertinib in Patients with Non-small Cell Lung Cancer

Population Pharmacokinetics and Exposure-response of Osimertinib in Patients with Non-small Cell Lung Cancer

Author(s): Kathryn Brown, Craig Comisar, Han Witjes, John Maringwa, Rik de Greef, Karthick Vishwanathan, Mireille Cantarini, Eugène Cox

Year: 2016年12月18日

関連コンテンツ

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

© 2025 Certara. All Rights Reserved. | 個人情報保護

Powered by Translations.com GlobalLink Web Software